BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clin Pharmacokinet 2019;58:431-49. [PMID: 30117017 DOI: 10.1007/s40262-018-0702-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Huo Z, Chen F, Liu P, Luo Z. Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone. Cancer Med 2022. [PMID: 36052569 DOI: 10.1002/cam4.5198] [Reference Citation Analysis]
2 Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, Khouri J, Maciejewski JP, Jha BK. Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers 2022;14:4082. [DOI: 10.3390/cancers14174082] [Reference Citation Analysis]
3 Ding C, Tang W, Xia B, Peng H, Liu Y, Wang J, Zheng X, Liu Y, Zhao L, He Y, Qi Z, Ren H, Tang H, Zhao P. High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses. Viruses 2022;14:1381. [DOI: 10.3390/v14071381] [Reference Citation Analysis]
4 Liu J, Zhao R, Jiang X, Li Z, Zhang B. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations. Biomolecules 2022;12:51. [DOI: 10.3390/biom12010051] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Bharate SS. Modulation of biopharmaceutical properties of drugs using sulfonate counterions: A critical analysis of FDA-approved pharmaceutical salts. Journal of Drug Delivery Science and Technology 2021;66:102913. [DOI: 10.1016/j.jddst.2021.102913] [Reference Citation Analysis]
6 Zhang G, Zhang L, Tan Y, Wang L, Cheng Z. Quantitative Assessment of the in vivo Dissolution Rate to Establish a Modified IVIVC for Isosorbide Mononitrate Tablets. J Pharm Sci 2021:S0022-3549(21)00594-3. [PMID: 34728173 DOI: 10.1016/j.xphs.2021.10.035] [Reference Citation Analysis]
7 Wang J, Fang Y, Fan RA, Kirk CJ. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism. Int J Mol Sci 2021;22:11595. [PMID: 34769030 DOI: 10.3390/ijms222111595] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
8 Bharate SS. Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts. Pharm Res 2021;38:1307-26. [PMID: 34302256 DOI: 10.1007/s11095-021-03080-2] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
9 Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2021;39:2430-42. [PMID: 34111952 DOI: 10.1200/JCO.21.00972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, van Rhee F, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Bařinová M, Kuhn M, Šilar J, Čápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol 2021;17:2499-512. [PMID: 33769076 DOI: 10.2217/fon-2020-1225] [Reference Citation Analysis]
11 Schwartz G, Shee K, Romo B, Marotti J, Kisselev A, Lewis L, Miller T. Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. Oncologist 2021;26:467-e924. [PMID: 33641211 DOI: 10.1002/onco.13733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Roeten MSF, van Meerloo J, Kwidama ZJ, Ter Huizen G, Segerink WH, Zweegman S, Kaspers GJL, Jansen G, Cloos J. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells 2021;10:665. [PMID: 33802801 DOI: 10.3390/cells10030665] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Fogli S, Galimberti S, Gori V, Del Re M, Danesi R. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacol Res 2021;167:105537. [PMID: 33684510 DOI: 10.1016/j.phrs.2021.105537] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Fan Y, Liang Z, Zhang J, You G. Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions. Pharmaceutics 2021;13:314. [PMID: 33670955 DOI: 10.3390/pharmaceutics13030314] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Wang Q, Dong Z, Su J, Huang J, Xiao P, Tian L, Chen Y, Ma L, Chen X. Ixazomib inhibits myeloma cell proliferation by targeting UBE2K. Biochem Biophys Res Commun 2021;549:1-7. [PMID: 33647537 DOI: 10.1016/j.bbrc.2021.02.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Bharate SS. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019. Drug Discov Today 2021;26:384-98. [PMID: 33221522 DOI: 10.1016/j.drudis.2020.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
17 Ling Y, Li R, Zhong J, Zhao Y, Chen Z. Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis. Drug Chem Toxicol 2020;:1-6. [PMID: 33108916 DOI: 10.1080/01480545.2020.1835945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac J Clin Oncol 2021;17:29-35. [PMID: 32920949 DOI: 10.1111/ajco.13459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Manda S, Yimer HA, Noga SJ, Girnius S, Yasenchak CA, Charu V, Lyons R, Aiello J, Bogard K, Ferrari RH, Cherepanov D, Demers B, Lu V, Whidden P, Kambhampati S, Birhiray RE, Jhangiani HS, Boccia R, Rifkin RM. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clin Lymphoma Myeloma Leuk 2020;20:e910-25. [PMID: 32912820 DOI: 10.1016/j.clml.2020.06.024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Ramadass V, Vaiyapuri T, Tergaonkar V. Small Molecule NF-κB Pathway Inhibitors in Clinic. Int J Mol Sci 2020;21:E5164. [PMID: 32708302 DOI: 10.3390/ijms21145164] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 27.5] [Reference Citation Analysis]
21 Lysenko Kozlovskaya LV, Rameev VV, Androsova TV. [Monoclonal gammapathy of renal significance (MGRS) at the current state: terminology, diagnosis and treatment]. Ter Arkh 2020;92:15-22. [PMID: 33346488 DOI: 10.26442/00403660.2020.06.000666] [Reference Citation Analysis]
22 Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Ann Hematol 2020;99:1793-804. [PMID: 32613281 DOI: 10.1007/s00277-020-04149-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Dash AB, Zhang J, Shen L, Li B, Berg D, Lin J, Avet-Loiseau H, Bahlis NJ, Moreau P, Richardson PG, Di Bacco A. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation. Eur J Haematol 2020;105:274-85. [PMID: 32350909 DOI: 10.1111/ejh.13435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
24 Sánchez G, Chalmers S, Ahumada X, Montecinos L, Olmedo I, Eisner V, Riveros A, Kogan MJ, Lavandero S, Pedrozo Z, Donoso P. Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia. PLoS One 2020;15:e0233591. [PMID: 32453773 DOI: 10.1371/journal.pone.0233591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther 2020;213:107579. [PMID: 32442437 DOI: 10.1016/j.pharmthera.2020.107579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
26 Terpos E, Ramasamy K, Maouche N, Minarik J, Ntanasis-Stathopoulos I, Katodritou E, Jenner MW, Plonkova H, Gavriatopoulou M, Vallance GD, Pika T, Kotsopoulou M, Kothari J, Jelinek T, Kastritis E, Aitchison R, Dimopoulos MA, Zomas A, Hajek R. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Ann Hematol 2020;99:1049-61. [PMID: 32236735 DOI: 10.1007/s00277-020-03981-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
27 O'Donoghue AJ, Bibo-Verdugo B, Miyamoto Y, Wang SC, Yang JZ, Zuill DE, Matsuka S, Jiang Z, Almaliti J, Caffrey CR, Gerwick WH, Eckmann L. 20S Proteasome as a Drug Target in Trichomonas vaginalis. Antimicrob Agents Chemother 2019;63:e00448-19. [PMID: 31451503 DOI: 10.1128/AAC.00448-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
28 Winzeler EA, Ottilie S. The proteasome as a target: How not tidying up can have toxic consequences for parasitic protozoa. Proc Natl Acad Sci U S A 2019;116:10198-200. [PMID: 31085658 DOI: 10.1073/pnas.1904694116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Vaxman I, Gertz M. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. Acta Haematol 2019;141:93-106. [PMID: 30650422 DOI: 10.1159/000495455] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 16.7] [Reference Citation Analysis]
30 Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng W, Kaiser M, Zweegman S, Mateos M, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV, Bar D, Basso A, Fantl D, He S, Horvath N, Lee C, Rowlings P, Taylor K, Spencer A, Cochrane T, Kwok F, Ramanathan S, Agis H, Zojer N, Kentos A, Offner F, Van Droogenbroeck J, Wu KL, Maiolino A, Martinez G, Zanella K, Capra M, Araújo S, Gregora E, Hajek R, Maisnar V, Pour L, Scudla V, Spicka I, Abildgaard N, Andersen N, Jensen BA, Helleberg C, Plesner T, Salomo M, Svirskaite A, Delarue R, Moreau P, Blau I, Goldschmidt H, Schieferdecker A, Teleanu V, Munder M, Röllig C, Salwender H, Fuhrmann S, Weisel K, Duerig J, Zeis M, Klein S, Reimer P, Schmidt C, Scheid C, Mayer K, Hoffmann M, Sosada M, Dimopoulos A, Delimpasi S, Kyrtsonis M, Anagnostopoulos A, Nagy Z, Illés Á, Egyed M, Borbényi Z, Mikala G, Dally N, Horowitz N, Gutwein O, Nemets A, Vaxman I, Shvetz O, Trestman S, Ruchlemer R, Nagler A, Tadmor T, Rouvio O, Preis M, Gay F, Cavo M, De Rosa L, Musto P, Cafro A, Tosi P, Offidani M, Corso A, Rossi G, Liberati AM, Bosi A, Suzuki K, Iida S, Nakaseko C, Ishikawa T, Matsumoto M, Nagai H, Sunami K, Chou T, Akashi K, Takezako N, Hagiwara S, Eom HS, Jo D, Kim JS, Lee JH, Min CK, Yoon SS, Yoon DH, Kim K, Zweegman S, Levin M, Vellenga E, Minnema M, Schjesvold F, Waage A, Haukås E, Grosicki S, Pluta A, Robak T, Marques H, Bergantim R, Campilho F, Chng WJ, Goh YT, Mcdonald A, Rapoport B, Álvarez Rivas MA, De Arriba de La Fuente F, González Montes Y, Martin Sanchez J, Mateos MV, Oriol Rocafiguera A, Rosinol L, San Miguel J, Pérez de Oteyza J, Encinas C, Alegre-amor A, López-guía A, Axelsson P, Carlson K, Stromberg O, Hansson M, Hveding Blimark C, Mueller R, Chen C, Liu T, Huang S, Wang P, Na Nakorn T, Prayongratana K, Beksac M, Unal A, Goker H, Sonmez M, Korenkova S, Chaidos A, Oakervee H, Sati H, Benjamin R, Wechalekar A, Garg M, Kaiser M, Ramasamy K, Cook G, Chantry A, Jenner M, Buadi F, Berryman R, Janakiram M. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet 2019;393:253-64. [DOI: 10.1016/s0140-6736(18)33003-4] [Cited by in Crossref: 104] [Cited by in F6Publishing: 117] [Article Influence: 34.7] [Reference Citation Analysis]
31 Jang HH. Regulation of Protein Degradation by Proteasomes in Cancer. J Cancer Prev 2018;23:153-61. [PMID: 30671397 DOI: 10.15430/JCP.2018.23.4.153] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
32 Lidumniece E, Withers-Martinez C, Hackett F, Collins CR, Perrin AJ, Koussis K, Bisson C, Blackman MJ, Jirgensons A. Peptidic boronic acids are potent cell-permeable inhibitors of the malaria parasite egress serine protease SUB1. Proc Natl Acad Sci U S A 2021;118:e2022696118. [PMID: 33975947 DOI: 10.1073/pnas.2022696118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]